PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

Cited by (622)

Items 201–300 of 622

1. The continuing role of chemotherapy in the management of advanced urothelial cancer
   Alfonso Gómez de Liaño, Ignacio Durán · 2018 · Therapeutic Advances in Urology
2. A pooled analysis of two phase II trials evaluating metformin plus platinum-based chemotherapy in advanced non-small cell lung cancer
   Anish B. Parikh, Kristen Ashley Marrone, Daniel Jacob Becker, Julie Renee Brahmer, David S. Ettinger, Benjamin Philip Levy · 2019 · Cancer Treatment and Research Communications
3. Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review
   Jin‐Yuan Shih, Akira Inoue, Rebecca Cheng, Rocio Varea, Sang-We Kim · 2020 · Cancers
4. Overexpression of PTEN may increase the effect of pemetrexed on A549 cells via inhibition of the PI3K/AKT/mTOR pathway and carbohydrate metabolism
   Bo Li, Junkai Zhang, Ya Su, Yiling Hou, Zhenguo Wang, Lin Zhao, Shengkai Sun, Hao Fu · 2019 · Molecular Medicine Reports
5. Hidden Treasures in “Ancient” Microarrays: Gene-Expression Portrays Biology and Potential Resistance Pathways of Major Lung Cancer Subtypes and Normal Tissue
   Konstantinos Kerkentzes, Vincenzo Lagani, Ioannis Tsamardinos, Mogens Vyberg, Oluf Dimitri Røe · 2014 · Frontiers in Oncology
6. Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario
   Yoanna Ivette Flores Vega, Diana Laura Páramo González, Sofía de la Caridad Alsina Sarmiento, Luis E. Alsina Tul, Iris Beatriz Inguanzo Valdés, J Rodríguez Machado, Ángel René Elejalde Larrinaga, Justo E Flores Rodríguez, Janet Lamadrid García, Danay Corrales Otero et al. · 2023 · Journal of Cancer
7. CT-based radiomics models may predict the early efficacy of microwave ablation in malignant lung tumors
   Fandong Zhu, Chen Guang Yang, Yang Xia, Jianping Wang, Jiajun Zou, Li Zhao, Zhenhua Zhao · 2023 · Cancer Imaging
8. Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction
   Pui San Tan, Gilberto De Lima Lopes Jr., Sanchalika Acharyya, Marcel Bilger, Benjamin Adam Haaland · 2015 · European Journal of Cancer
9. Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?—current evidence and future perspectives
   Grainne Mary O'Kane, Natasha B. Leighl · 2016 · Translational Lung Cancer Research
10. A review of systemic anticancer therapy in disease palliation
    Caroline Usborne, Anna P. Mullard · 2017 · British Medical Bulletin
11. Rapidly Changing Treatment Algorithms for Metastatic Nonsquamous Non-Small-Cell Lung Cancer
    Barbara L. Melosky · 2018 · Current Oncology
12. Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer
    Barbara L. Melosky · 2017 · Frontiers in Oncology
13. Treatment of Stage IIIA Non–Small-Cell Lung Cancer: A Concise Review for the Practicing Oncologist
    Rafael Santana-Dávila, Renato G. Martins · 2016 · Journal of Oncology Practice
14. PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
    Martin Reck, Luis G Paz-Ares, Filippo de Marinis, Olivier Molinier, Tarini Prasad Sahoo, Eckart Laack, William J. John, Annamaria Hayden Zimmermann, Carla Visseren‐Grul, Cesare Gridelli · 2014 · Journal of Thoracic Oncology
15. Novel Multitarget Therapies for Lung Cancer and Respiratory Disease
    Masako Yumura, Tatsuya Nagano, Yoshihiro Nishimura · 2020 · Molecules
16. First-Line Pembrolizumab with or Without Platinum Doublet Chemotherapy in Non-Small-Cell Lung Cancer Patients with PD-L1 Expression ≥50%
    R. Descourt, CHRISTOS CHOUAID, Maurice Pérol, Benjamin Besse, Laurent Greillier, Olivier Bylicki, Charles Ricordel, Florian Guisier, R. Gervais, Roland Schött et al. · 2021 · Future Oncology
17. Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer
    Rebekah Rittberg, Bonnie O. Leung, Zamzam Salam Al-Hashami, Cheryl Ho · 2022 · Frontiers in Oncology
18. Advances in treatment of mesothelioma
    C. Maggioni, G. Barletta, Erika Rijavec, Federica Biello, Elisa Gualco, Francesco Grossi · 2016 · Expert Opinion on Pharmacotherapy
19. Pemetrexed Plus Platinum for Patients With Advanced Non-small Cell Lung Cancer and Interstitial Lung Disease
    Tetsuo Fujita, Tsuguko Kuroki, Nami Hayama, Yuka Shiraishi, Hiroyuki Amano, Makoto Nakamura, SATOSHI HIRANO, Hiroshi Tabeta, Sukeyuki Nakamura · 2019 · In Vivo
20. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study
    Hortense Chevalier, Angélique Vienot, Astrid Lièvre, Julien Edeline, Farid El Hajbi, Charlotte Peugniez, Déwi Vernerey, Aurélia Meurisse, Pascal R. Hammel, Cindy Neuzillet et al. · 2020 · The Oncologist
21. KRAS oncogene may be another target conquered in non‐small cell lung cancer ( NSCLC )
    Hanxiao Chen, Jun Zhao · 2020 · Thoracic Cancer
22. Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189
    Edward B. Garon, Joachim G.J.V. Aerts, Jong Seok Kim, Catherine Elizabeth Muehlenbein, Patrick M. Peterson, Maria Teresa Rizzo, Shirish M. Gadgeel · 2021 · Lung Cancer
23. Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer
    Young Saing Kim, Eun Kyung Cho, Hyun Sun Woo, Junshik Hong, Hee Kyung Ahn, Inkeun Park, Sun Jin Sym, Sun Young Kyung, Shin Myung Kang, Jeong-Woong Park et al. · 2015 · Cancer Research and Treatment
24. Effect of renal function on pemetrexed-induced haematotoxicity
    Yosuke Ando, Takahiro Hayashi, Moeko Ujita, Sumie Murai, Hideki Ohta, Kaori Ito, Teppei Yamaguchi, M Funatsu, Yoshiaki Ikeda, Kazuyoshi Imaizumi et al. · 2016 · Cancer Chemotherapy and Pharmacology
25. Treatment of advanced Gall bladder cancer in the real world—can continuation chemotherapy improve outcomes?
    Vikas S Ostwal, Rakesh Pinninti, Anant Ramaswamy, Nitin Shetty, Mahesh Goel, Shraddha Patkar, Jimmy Mirani, Chaitali Nashikkar, Shripad Dinanath Banavali · 2017 · Journal of Gastrointestinal Oncology
26. Surgical approach in the oligometastatic patient
    Duilio Divisi, Mirko Barone, Gino Zaccagna, Francesca Gabriele, Roberto Crisci · 2018 · Annals of Translational Medicine
27. Prospects and progress of atezolizumab in non-small cell lung cancer
    Johan Vansteenkiste, Els Wauters, Keunchil Park, Achim Rittmeyer, Alan B. Sandler, Alexander I. Spira · 2017 · Expert Opinion on Biological Therapy
28. Safety, Feasibility, and Efficacy of Capecitabine Maintenance in Patients With Advanced Gastric Cancer: A Retrospective Study
    Orhan Önder Eren, Mehmet Akif Öztürk, Özlem Sönmez, Başak Oyan · 2014 · American Journal of Therapeutics
29. Pulmonary Resection for Synchronous M1b-cStage IV Non-Small Cell Lung Cancer Patients
    Masafumi Yamaguchi, Makoto Edagawa, Yuzo Suzuki, Ryo Toyozawa, Fumihiko Hirai, Kaname Nosaki, Takashi Seto, Mitsuhiro Takenoyama, Yukito Ichinose · 2016 · The Annals of Thoracic Surgery
30. Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies
    Corey Jay Langer, Luis G Paz-Ares, Antoinette J. Wozniak, Cesare Gridelli, Filippo de Marinis, Jean-Louis Pujol, Belén San Antonio, Jian Chen, Jingyi Liu, Ana Belen Oton et al. · 2017 · Clinical Lung Cancer
31. A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
    Kwai Han Yoo, Su Jin Lee, Jinhyun Cho, Ki Hyeong Lee, Keon Uk Park, Ki Hwan Kim, Eun Kyung Cho, Yoon Hee Choi, Hye Ryun Kim, Hoon‐Gu Kim et al. · 2018 · Cancer Research and Treatment
32. Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model
    Daniel Moldaver, Manjusha Vrindini Hurry, William Kenneth Evans, Parneet Kaur Cheema, Randeep S. Sangha, Ronald L. Burkes, Barbara L. Melosky, Diana Tran, Darryl Boehm, Jaya Venkatesh et al. · 2019 · Lung Cancer
33. NCCN Guidelines Version 1.2015 Panel Members Non-Small Cell Lung Cancer
    David S. Ettinger, Sidney Kimmel, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thierry Marie Jahan et al. · 2014
34. Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Xingsheng Hu, Ke Pu, Xuqin Feng, Shimin Wen, Xi Bo Fu, Cuihua Guo, Wenwu He · 2016 · PLoS ONE
35. Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
    Tian Zeng, Qin Qin, Zhiheng Bian, Jianjun Li · 2019 · Artificial Cells Nanomedicine and Biotechnology
36. Lung cancer in the emergency department
    JEREMY R WALDER, Saadia A. Faiz, Marcelo Sandoval · 2023 · Emergency Cancer Care
37. A folylpoly-γ-glutamate synthase single nucleotide polymorphism associated with response to pemetrexed treatment combined with platinum for non-small cell lung cancer
    Satoshi Fukuda, Tetsuya Oguri, Eiji Kunii, Kazuki Sone, Takehiro Uemura, Osamu Takakuwa, Ken Maeno, Yoshihiro Kanemitsu, Hirotsugu Ohkubo, Masaya Takemura et al. · 2016 · Lung Cancer
38. Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM)
    Francesco Facchinetti, Sara Pilotto, Giulio Metro, Editta Baldini, Luca Bertolaccini, Federico Cappuzzo, Angelo Delmonte, Stefano Gasparini, Alessandro Inno, Antonio Marchetti et al. · 2019 · Tumori Journal
39. A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002)
    Yasuyuki Ikezawa, Hajime Asahina, Satoshi Oizumi, Masahiro Watanabe, Kei Takamura, Yasutaka Kawai, Noriyuki Yamada, Toshiyuki Harada, Ichiro Kinoshita, Yuka Fujita et al. · 2017 · Cancer Chemotherapy and Pharmacology
40. Treatment patterns, duration and outcomes of pemetrexed maintenance therapy in patients with advanced NSCLC in a real-world setting
    Katherine B. Winfree, Aracelis Z. Torres, Yajun Emily Zhu, Catherine Elizabeth Muehlenbein, Himani Aggarwal, Susan Woods, Amy P. Abernethy · 2018 · Current Medical Research and Opinion
41. Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line – Indian consensus statement update
    Kumar Prabhash · 2019 · South Asian Journal of Cancer
42. Racotumomab in Non-Small Cell Lung Cancer as Maintenanceand Second-Line Treatment
    Haslen Hassiul Cáceres Lavernia, Elia Nenínger Vinageras, Leslie M. Varona-Rodríguez, Yoli A. Olivares-Romero, Irlis Sánchez-Rojas, Zaima Mazorra, Denenke Basanta Bergolla, Dayanis Duvergel Calderín, Boris Luis Torres Cuevas, Concepción del Castillo Carrillo · 2021 · MEDICC Review
43. How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
    Biagio Ricciuti, Alessia Mira, Elisa Andrini, Pietro Scaparone, Sandra Vietti Michelina, Federica Pecci, Luca Cantini, Andrea De Giglio, Giuseppe Lamberti, Chiara Ambrogio et al. · 2022 · Drugs in Context
44. Maintenance Therapy Improves Survival Outcomes in Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of 14 Studies
    Shun Lü, Yongfeng Yu, Zhiwei Chen, Xiangyun Ye, Ziming Li, Xiaomin Niu · 2015 · Lung
45. Single-agent maintenance therapy for advanced non-small cell lung cancer (NSCLC): a systematic review and Bayesian network meta-analysis of 26 randomized controlled trials
    Qinxue Wang, Haobin Huang, Xiaoning Zeng, Yuan Ma, Xin Zhao, Mao Huang · 2016 · PeerJ
46. Defining Aggressive Or Early Progressing Nononcogene-Addicted Non-Small-Cell Lung Cancer: A Separate Disease Entity?
    Martin Reck, Keith M. Kerr, Christian Grohé, Christian Manegold, Nick Pavlakis, Luis G Paz-Ares, Rudolf Maria Huber, Sanjay Popat, N. Thatcher, Keunchil Park et al. · 2019 · Future Oncology
47. Complex Decisions for First-Line and Maintenance Treatment of Advanced Wild-Type Non-Small Cell Lung Cancer
    Ryan D. Gentzler, Melissa Lynne Johnson · 2015 · The Oncologist
48. First-Line Systemic Therapy for Non–Small Cell Lung Cancer
    Rebecca Suk Heist · 2016 · Hematology/Oncology Clinics of North America
49. Value-Based Care in Lung Cancer
    Keith D. Eaton, Barbara Jagels, Renato G Martins · 2016 · The Oncologist
50. Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non–Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care
    Jyoti D. Patel, Luis G Paz-Ares, Ralph Zinner, Fabrice Barlési, Andrew G. Koustenis, Coleman K. Obasaju · 2018 · Clinical Lung Cancer
51. The effect of rapid infusion of cisplatin on nephrotoxicity in patients with lung carcinoma
    Eveline S. Mense, Arthur A J Smit, Mirjam Crul, Eric J. F. Franssen · 2018 · Journal of Clinical Pharmacy and Therapeutics
52. Does Platinum-Based Chemotherapy Still Have a Role in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer?
    Aaron Elliott Lisberg, Edward B. Garon · 2019 · Journal of Clinical Oncology
53. A Single-Arm Phase II Study to Evaluate Efficacy and Safety of First-Line Treatment With DCVAC/LuCa, Standard of Care Chemotherapy and Shenqi Fuzheng Injection in Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer Patients
    Qing Liu, Yanni Lou, Liya Li, Guowang Yang, Huijuan Cui, Zhiqiang Cheng, Yuan Li, Meng Liu, Chao Deng, Donggui Wan et al. · 2022 · Integrative Cancer Therapies
54. The Change in Paradigm for NSCLC Patients with EML4–ALK Translocation
    Alessandra Bearz, Elisa De Carlo, Alessandro Del Conte, Michele Spina, Valentina Da Ros, Elisa Bertoli, Alberto Revelant, Brigida Stanzione, Umberto Tirelli · 2022 · International Journal of Molecular Sciences
55. State of the art and new perspectives in surgical treatment of lung cancer: a narrative review
    Francesco Petrella, Stefania Rizzo, Monica Casiraghi, Claudia Bardoni, Shehab Mohamed, Valeria Musso, Emanuele Simonini, Lorenzo Spaggiari · 2022 · Translational Cancer Research
56. Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression
    Chung‐Yu Chen, Ying-Yin Chen, Jeremy J.W. Chen, Kuan‐Yu Chen, Chao‐Chi Ho, Jin‐Yuan Shih, Yih‐Leong Chang, Chong‐Jen Yu, Pan‐Chyr Yang · 2017 · Oncotarget
57. Current Smoking has a Detrimental Effect on Survival for Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) negative Advanced non-squamous Non-small Cell Lung Cancer (NSCLC) Patients Treated with Pemetrexed Continuation Maintenance
    Liping Lin, Juanjuan Zhao, Jiazhu Hu, Guorong Zou, Fuxi Huang, Jianjun Han, Yan He, Xiaolong Cao · 2018 · Journal of Cancer
58. High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study
    Issei Sumiyoshi, Takahiro Okabe, Shinsaku Togo, Haruhi Takagi, Hiroaki Motomura, Yusuke Ochi, Naoko Shimada, Mizuki Haraguchi, Rina Shibayama, Yuichi Fujimoto et al. · 2021 · Journal of Translational Medicine
59. Non-Small-Cell Lung Cancer Treatment
    Ryo Koyama, Kazuhisa Takahashi · 2016 · Juntendō Igaku/Juntendo igaku
60. Reality Check for Pemetrexed and Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer
    Nevin Murray · 2014 · Journal of Clinical Oncology
61. Show me the roads and give me a road map: Development of a patient conversation tool to improve lung cancer treatment decision-making
    Sara E. Golden, Natalie G. Disher, Nathan F. Dieckmann, Karen Eden, Daniel D. Matlock, Kelly C. Vranas, Christopher G. Slatore, Donald Richard Sullivan · 2022 · PEC Innovation
62. Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial
    Tianqing Chu, Hua Zhong, Zhuang Yu, Jing Wang, Yanqiu Zhao, Xiaoqian Mu, Xinmin Yu, Xun Shi, Qingming Shi, Maojing Guan et al. · 2025 · 癌症：英文版
63. Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results
    Alice Pasini, Angelo Delmonte, Anna Tesei, Daniele Calistri, Emanuele� Giordano · 2015 · Drugs
64. Second-Line Therapy in Non–Small-Cell Lung Cancer: The DELTA Between Different Genotypes Widens
    Alona Zer, Natasha B. Leighl · 2014 · Journal of Clinical Oncology
65. New options for combination therapy for advanced non-squamous NSCLC
    Antônio Rossi · 2019 · Expert Review of Respiratory Medicine
66. Changing paradigm in advanced and metastatic non-small cell lung cancer
    Dipesh Uprety, Kaushal Parikh, Anita Sawkar, Anastasios Dimou, Konstantinos Leventakos · 2020 · Journal of Thoracic Disease
67. Maintenance in gastric cancer: New life for an old issue?
    Giandomenico Roviello, Maria Grazia Rodriquenz, Giuseppe Aprile, Alberto D’Angelo, Franco Roviello, Stefania Nobili, Enrico Mini, Italo Sarno, Karol Połom · 2021 · Critical Reviews in Oncology/Hematology
68. Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study
    Xiaodong Gu, Zhiyong Shi, Lan Shao, Yuxin Zhang, Yiping Zhang, Zhengbo Song, Wenxian Wang, Guangyuan Lou · 2022 · BMC Cancer
69. Estimated Creatinine Clearance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer
    Chung‐Yu Chen, Jou‐Wei Lin, Jenq‐Wen Huang, Kuan‐Yu Chen, Jin‐Yuan Shih, Chong‐Jen Yu, Pan‐Chyr Yang · 2015 · Clinical Lung Cancer
70. Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design
    Rohit Lal, Nawel Bourayou, Gunnar Hillerdal, Marianne C. Nicolson, Anders Vikström, Maria Lorenzo, Yulia Dyachkova, Susana Barriga, Carla Visseren‐Grul · 2013 · Health and Quality of Life Outcomes
71. Maintenance or Consolidation Therapy for Non–Small-Cell Lung Cancer: A Meta-Analysis Involving 5841 Subjects
    Cuicui Zhang, Chun Huang, Jing Wang, Xinyue Wang, Kai Li · 2015 · Clinical Lung Cancer
72. Should chemotherapy plus immune checkpoint inhibition be the standard front‐line therapy for patients with metastatic non–small cell lung cancer?
    Sarah B. Goldberg, Roy S. Herbst · 2018 · Cancer
73. Hedgehog Pathway Activation Might Mediate Pemetrexed Resistance in NSCLC Cells
    Yichao Liu, Rudolf Maria Huber, Rosemarie Kiefl, Amanda Tufman, Diego Erich Kauffmann-Guerrero · 2020 · Anticancer Research
74. Folate receptor-positive circulating tumor cells as a predictive biomarker for the efficacy of first-line pemetrexed-based chemotherapy in patients with non-squamous non-small cell lung cancer
    Xiaoxia Chen, Fei Zhou, Xuefei Li, Guohua Yang, Chao Zhao, Wei Li, Fenying Wu, Jia Yu, Guanghui Gao, Jiayu Li et al. · 2020 · Annals of Translational Medicine
75. A Phase I Study of the Non-Receptor Kinase Inhibitor Bosutinib in Combination with Pemetrexed in Patients with Selected Metastatic Solid Tumors
    Nagla Abdel Karim, Asad Ullah, Hongkun Wang, Mahran Shoukier, Steven Pulliam, Khaled Ahmed, Nikhil Patel, John Charles Morris · 2022 · Current Oncology
76. Association between Gene Expression Profiles and Clinical Outcome of Pemetrexed-Based Treatment in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: Exploratory Results from a Phase II Study
    Dean Anthony Fennell, Scott P. Myrand, Tuan S. Nguyen, David Raymond Ferry, Keith M. Kerr, Perry Maxwell, Stephen D. Moore, Carla Visseren‐Grul, Mayukh Das, Marianne C. Nicolson · 2014 · PLoS ONE
77. Is the Chemotherapy Era in Advanced Non-Small Cell Lung Cancer Really Over? Maybe not Yet
    Giuseppe Lo Russo, Martina Imbimbo, Marina Chiara Garassino · 2016 · Tumori Journal
78. Opportunities for Precision Dosing of Cytotoxic Drugs in Non-Small Cell Lung Cancer: Bridging the Gap in Precision Medicine
    Mart P. Kicken, Maarten J. Deenen, Anthonie J. van der Wekken, Ben E.E.M. van den Borne, Michel M. van den Heuvel, Rob ter Heine · 2025 · Clinical Pharmacokinetics
79. Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence
    Yosuke Togashi, Hidetoshi Hayashi, Kazuhiko Nakagawa, Kazuto Nishio · 2014 · Drug Design Development and Therapy
80. A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients
    Rajiv Kumar, Shir Kiong Lu, Anna Rachel Minchom, Adam Sharp, Michael Davidson, Ranga Gunapala, Timothy A. Yap, Jaishree Bhosle, Sanjay Popat, Mary E.R. O'Brien · 2015 · Cancer Chemotherapy and Pharmacology
81. How Preconceptions About Lung Cancer Treatment Interact With Medical Discourse for Patients Who Accept Chemotherapy?
    Jean-Louis Pujol, Jean-Pierre Mérel, Caroline Roth · 2016 · Psycho-Oncology
82. Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer
    Luis G Paz-Ares, Annamaria Hayden Zimmermann, Tudor–Eliade Ciuleanu, Paul A. Bunn, Belén San Antonio, Jonathan S. Denne, Nancy L. Iturria, William J. John, Giorgio V. Scagliotti · 2016 · Lung Cancer
83. Deep sequencing and automated histochemistry of human tissue slice cultures improve their usability as preclinical model for cancer research
    Susann Haehnel, Kristin Reiche, Dennis Löffler, Andreas Horn, Conny Blumert, Sven-Holger Puppel, Nicole C. Kaiser, Felicitas Rapp, Michael Rade, Friedemann Horn et al. · 2019 · Scientific Reports
84. The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update
    Alexios Matikas, Vassilis Georgoulias, Athanasios Panayotis Kotsakis · 2016 · Expert Review of Respiratory Medicine
85. Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer
    Noboru Yamamoto, Kōichi Goto, Makoto Nishio, Kenichi Chikamori, Toyoaki Hida, Makoto Maemondo, Nobuyuki Katakami, Toshiyuki Kozuki, Hiroshige Yoshioka, Takashi Seto et al. · 2016 · International Journal of Clinical Oncology
86. Validity of using immunohistochemistry to predict treatment outcome in patients with non-small cell lung cancer not otherwise specified
    Takahiro Ota, Keisuke Kirita, Reiko Matsuzawa, Hibiki Udagawa, Shingo Matsumoto, Kiyotaka Yoh, Seiji Niho, Genichiro Ishii, Kōichi Goto · 2019 · Journal of Cancer Research and Clinical Oncology
87. Non-small Cell Lung Cancer
    Apichat Tantraworasin, Sarawut Kongkarnka, Nirush Lertprasertsuke, Yutthaphan Wannasopha, Juntima Euathrongchit, Thatthan Suksombooncharoen, Somcharoen Saeteng, Sophon Siwachat, Busayamas Chewaskulyong · 2019 · Springer eBooks
88. Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC
    Collin Michael Blakely, Jonathan Wesley Riess · 2019 · Expert Review of Anticancer Therapy
89. Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study)
    Denis Moro‐Sibilot, Clarisse Audigier-Valette, Patrick Merle, Élisabeth Quoix, Pierre-Jean Souquet, Fabrice Barlési, CHRISTOS CHOUAID, Olivier Molinier, Jaafar Bennouna, A. Lavolé et al. · 2015 · Lung Cancer
90. The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients
    Tomasz Kucharczyk, Paweł Adam Krawczyk, Tomasz Powrózek, Dariusz Mirosław Kowalski, Rodryg Ramlau, Ewa Kalinka‐Warzocha, Magdalena Knetki‐Wróblewska, Kinga Winiarczyk, Maciej Jerzy Krzakowski, Janusz Milanowski · 2015 · Pathology & Oncology Research
91. Developments in pharmacotherapy for treating metastatic non-small cell lung cancer
    Antônio Rossi, Paola Claudia Sacco, Giuseppe Santabarbara, Assunta Sgambato, Francesca Casaluce, Giovanni Palazzolo, Paolo Maione, Cesare Gridelli · 2017 · Expert Opinion on Pharmacotherapy
92. KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1–49%
    Daniel Morgensztern · 2019 · Journal of Thoracic Disease
93. Clinical prognostic factors in surgically treated oligometastatic non-small cell lung cancer: a systematic review
    Luca Bertolaccini, Monica Casiraghi, Giulia Sedda, Filippo de Marinis, Lorenzo Spaggiari · 2021 · Translational Lung Cancer Research
94. Successful first-line treatment of simultaneous multiple primary malignancies of lung adenocarcinoma and renal clear cell carcinoma: A case report
    Xiaojun Ye, Xiangliang Liu, Na Yin, Wei Song, Jin Wei LU, Yi‐Hsin Yang, Xiao Chen · 2022 · Frontiers in Immunology
95. Sublobar Resection, Stereotactic Body Radiation Therapy, and Percutaneous Ablation Provide Comparable Outcomes for Lung Metastasis-Directed Therapy
    Hunter C. Gits, Mitra A. Khosravi Flanigan, Jamie D. Kapplinger, Janani S. Reisenauer, Patrick W. Eiken, William G. Breen, Linh H. Vu, Brian T. Welch, William Scott Harmsen, Courtney N. Day et al. · 2023 · CHEST Journal
96. A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France
    Kaisa Taipale, Katherine B. Winfree, Mark E. Boye, Mickaël Basson, Ghassan Sleilaty, James Eaton, Rachel Evans, CHRISTOS CHOUAID · 2017 · ClinicoEconomics and Outcomes Research
97. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms
    Wolfgang Schütte, Sylvia Gutz, Wiebke Nehls, Torsten Gerriet Blum, Wolfgang M. Brückl, Nina Buttmann‐Schweiger, Reinhard Büttner, Petros Christopoulos, Sandra Delis, K.-M. Deppermann et al. · 2023 · Pneumologie
98. Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer
    Seigo Minami, Takashi Kijima · 2015 · Lung Cancer Targets and Therapy
99. Efficacy of S-1 in non-small cell lung cancer
    Masaaki Kawahara · 2014 · Expert Opinion on Pharmacotherapy
100. Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non–Small Cell Lung Cancer
     Anthony M. Brade, Robert Malcolm MacRae, Scott Andrew Laurie, Andrea Bezjak, Ronald L. Burkes, Quincy Siu-Chung Chu, John R. Goffin, John Cho, Andrew J. Hope, Alexander Y. Sun et al. · 2015 · Clinical Lung Cancer